Reproductive endocrinologists play key role in fertility treatment The Endocrine Society endorses the Right to IVF Act, which was introduced by Senators Cory Booker (D-NJ), Patty Murray (D-WA) and Tammy Duckworth (D-IL) to protect and expand nationwide access to fertility treatment, including in vitro fertilization (IVF), and urges the Senate to pass the Right to...
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors Veracyte, Inc., announced new research findings suggesting the potential of novel molecular signatures to identify patients with thyroid nodules or cancer who have aggressive disease....
Instead of viewing being female, Latina, and LGBTQ+ as a hindrance in the realm of surgery, Julie Ann Sosa, MD, MA, FACS, instead proudly asserts that they are actually “superpowers.” And she is determined to harness those powers so that future generations will have an easier path. Pursuing a career in medicine is no easy...
A year seems to go by quickly in today’s fast-paced world, but the Endocrine Society always manages to accomplish a huge amount in that trip around the sun! Even the recent total eclipse of said sun did not slow us down! As I reflect on my soon-to-conclude presidential tenure, I’m amazed at the sheer number... On June 3, during ENDO 2024 in Boston, “Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline” was officially released. While this new guideline suggests supplements might benefit specific populations and questions the need for testing, it also suggests that more research is needed to determine optimal levels for specific health...
Guideline recommends vitamin D higher than the recommended daily allowance for children, pregnant people, adults over 75 and adults with prediabetes Healthy adults under the age of 75 are unlikely to benefit from taking more than the daily intake of vitamin D recommended by the Institutes of Medicine (IOM) and do not require testing for...
TED Patients Report Maintained Improvement 2 Years After Teprotumumab Infusions
Most patients with thyroid eye disease treated with teprotumumab didn’t require additional treatments nearly two years later, according to industry-supported research being presented Sunday at ENDO 2024 in Boston, Mass., and published in the journal Thyroid. “Thyroid eye disease is a lifelong autoimmune disease that can worsen or flare, regardless of how it has been treated....
An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Xerix Announces Results of Once-Weekly Subcutaneous Hypothyroidism Therapy On May 30, Xeris Biopharma Holdings, Inc., announced topline results from its recently completed Phase 2 multi-center, open label, study of XP-8121 for the treatment of adults with hypothyroidism. XP-8121 employs the Company’s...
